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Abstract
Background: Most valid methods to measure treatment adherence require time and resources,
and they are not easily applied in highly demanding Primary Health Care Clinics (PHCC). The
objective of this study was to determine sensitivity, specificity, predictive values, likelihood ratios,
and post-test probabilities of two novel questionnaires as proxy measurements of treatment
adherence in Type-2 diabetic patients.
Methods: Two questionnaires were developed by a group of experts to identify the patient's
medical prescription knowledge (knowledge) and their attitudes toward treatment adherence
(attitudes) as proxy measurements of adherence. The questionnaires were completed by patients
receiving care in PHCC pertaining to the Mexican Institute of Social Security in Aguascalientes
(Mexico). Pill count was used as gold standard. Participants were selected randomly, and their oral
hypoglycemic prescriptions were studied. The main outcome measures for each questionnaire
were sensitivity, specificity, predictive values, likelihood ratios, and post-test probabilities, all as an
independent questionnaire test and in a serial analysis.
Results: Adherence prevalence was 27.0% using pill count. Knowledge questionnaire showed the
highest sensitivity (68.1%) and negative predictive value (82.2%), the lowest negative likelihood ratio
(0.58) and post-test probability for a negative result (0.16). Serial analysis showed the highest
specificity (77.4%) and positive predictive value (40.1%) as well as the highest positive likelihood
ratio (1.8) and post-test probability for a positive result (0.39).
Conclusion: Medical Prescription Knowledge questionnaire showed the best performance as
proxy measurement to identify non-adherence in type 2 diabetic patients regarding negative
predictive value, negative likelihood ratio, and post-test probability for a negative result. However,
Medical Prescription Knowledge questionnaire performance may change in contexts with higher
adherence prevalence. Therefore, more research is needed before using this method in other
contexts.
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Background
In the clinical guidelines for the care of patients with Type-
2 Diabetes Mellitus (DM2), the Mexican Institute of Social
Security (Instituto Mexicano del Seguro Social, IMSS)
establishes the evaluation of treatment adherence as one
of the 29 care actions [1]. This is motivated by the fact that
treatment adherence in diabetic patients is associated with
lower HbA1c levels [2] and a decrease in the risk of com-
plications [3].
Direct methods used to measure treatment adherence
include the measurement of drug serum concentration, or
the use of chemical markers in tablets. However, these
methods are expensive and they also have known limita-
tions [4], restricting their daily use in primary health care
clinics (PHCC). Electronic monitoring is one of the most
commonly used indirect methods, and it is the closest
method to a gold standard [5]. Such electronic monitor-
ing provides detailed information about the use of medi-
cations, keeping records of dates and hours at which the
bottles were opened. While its usefulness has been dem-
onstrated in patients who require long-term treatment [5-
7], the expense of this method in clinical settings is a seri-
ous drawback. Pill counts require at least two home visits
to the patient [6,7], which also makes this impractical in
a high-demand PHCC setting. Other indirect methods
such as clinical outcomes [8] and patient self-reports tend
to overestimate adherence, unlike electronic monitoring
[6].
A questionnaire to measure adherence has been devel-
oped, based on the level of disease knowledge [9]. How-
ever, this questionnaire tends to underestimate adherence
prevalence and while its sensitivity is adequate, it has a
low specificity and negative predictive value [10,11]. Sim-
ilarly, a questionnaire to measure adherence was devel-
oped on the basis of behavioral attitudes regarding the
intake of medication [12], but this tends to overestimate
adherence prevalence and between 47 and 67% of
patients are misclassified as adherent [10,11].
The objective of this study was to determine the sensitiv-
ity, specificity, predictive values, likelihood ratios, and
post-test probabilities of two novel questionnaires as a
proxy measurement of treatment adherence in Type-2 dia-
betic patients.
Methods
Development of the questionnaires
A group of experts developed two questionnaires as proxy
measurements of adherence through the identification of
patient's medical prescription knowledge (knowledge)
and attitudes toward treatment adherence (attitudes)
using a consensus-panel process. The questionnaires were
written in Spanish. The first phase of development
included item generation by diabetologists, primary-care
physicians, and psychologists. In the first questionnaire,
three questions were formulated that assessed the
patient's knowledge of the name of the medication pre-
scribed to control their diabetes (KQ1), its dosage (KQ2),
and the dosing interval (KQ3). The second questionnaire
addressed six domains that were identified by the experts
in a thorough search for information about the causes of
nonadherence: well-being/discomfort (AQ1, AQ2); belief
about the damage caused by medication (AQ3); the dia-
betes-treatment complications relationship (AQ4, AQ5);
barriers/facilitators to take medication (AQ6, AQ7); acces-
sibility to healthcare and medical treatment (AQ8, AQ9);
and doctor-patient agreements about treatment (AQ10,
AQ11). Experts developed eleven questions, two of which
were reworded from the Morisky scale [12]. The experts
agreed that both questionnaires had good content valid-
ity.
The second phase of questionnaires development was face
validity. Patients understanding of questions on written
and oral formats were explored. As reading problems were
identified, interviews were used for data collection. These
questionnaires were completed by a convenience sample
of 30 diabetic patients. They were asked to identify ambig-
uous items. Based on their feedback, some of the ques-
tions were reworded to eliminate ambiguous phrasing.
The final phase was done in order to provide support for
the construct validity of the attitudes questionnaire. We
carried out a principal component analysis followed by a
varimax rotation, to explore if the attitudes questionnaire
domains were valid. An item was considered to be corre-
lated on a domain if factor loading was greater than 0.4
[13]. This analysis yielded six factors with eigenvalues > 1,
explaining 77.5% of the variance [see Additional file 1].
Therefore, the questionnaire structure identified by the
experts through literature was confirmed, and it showed
construct validity. Further, a Cronbach's alpha was used to
examine the internal consistency of the attitude question-
naire, which was acceptable (alpha = 0.74).
Each question of attitudes scale was rated on a five-point
(1–5) Likert scale of agreement, ranging from "strongly
disagree" to "strongly agree". Questionnaires' English ver-
sion [see Additional file 2] is a translation from the
authors, and had not been adapted to this language; the
originals Spanish questionnaires are available from the
first author.
Context and participants
In Mexico, IMSS provides health services to more than
50% of the population; diabetes was the second reason
for consultation in primary health care in 2001. Type-2
diabetes accounts for over 90% of the cases. This studyBMC Public Health 2009, 9:38 http://www.biomedcentral.com/1471-2458/9/38
Page 3 of 8
(page number not for citation purposes)
was carried out in PHCC situated in the urban areas of
Aguascalientes, Mexico.
Participants were randomly selected from a Register of
Chronic Degenerative Patients in the IMSS; this database
had approximately 27,850 patients with diabetes in
Aguascalientes during 2001.
Inclusion criteria for all participants were: patients ≥40
years of age, who had been diagnosed with DM2 at least
one year earlier, who received oral hypoglycemic medica-
tion (glibenclamide and/or metformin), and who did not
use insulin or suffer from chronic complications.
We calculated the sample size taking into account each
oral hypoglycemic prescribed. Due to some diabetic
patients having monotherapy or polytherapy prescrip-
tion, the number of medications in our study is larger
than the number of patients. Further, we took into
account the prevalence of adherence reported by Donnan
et al. [14] in patients with polytherapy (35%). With this
prevalence being low, it is expected that the question-
naires are able to detect most of the patients who do not
adhere [15]. As a result, the sample size calculation was
done to identify a specificity of 80% to detect nonadher-
ence (95% confidence level) and a precision of 5%. The
sample size was of 379 medications to study. EPIDAT 3.1
[16] was used to calculate the size and power of the sam-
ple, which uses the proposed formulae by Obuchowsky N
[17] for studies of test accuracy.
Data collection
Two health professionals were trained to carry out home
visits and patient interviews. In the PHCC, the interview-
ers invited the patients to participate and explained the
details of their participation in the research by means of
an informed consent form.
In the first home visit, interviewers recorded the number
of pills that patients had received, and also completed the
questionnaires about personal characteristics, medical
prescription knowledge, and attitudes to treatment adher-
ence. Over three months and each month, interviewers
visited the patients again to register the pills that patients
received in their consultation; at the last visit, they regis-
tered the pill count.
The family physician's prescriptions were verified from
medical records at the PHCC (type of oral hypoglycemic,
dosage, and dosing interval).
Statistical analysis
The true level of treatment adherence was identified by
means of the pill count. As a result, this method gave the
percentage of adherence which was calculated by dividing
the difference in the number of pills in the first home visit,
and the pills remaining at the last home visit by the
number of pills prescribed for the time interval, and mul-
tiplying the result by 100. Pill count percentages were con-
verted to a categorical scale, as proposed by Mason [6]. As
such, a patient who took between 90 and 105% of the
medication prescribed was classified as having good
adherence, and a patient that took < 90% or > 105% was
classified as having poor adherence.
Proxy measurements of treatment adherence
To classify attitudes, answers to the questionnaire were
added and divided by the number of items. A result of 4
or 5 was classified as a positive attitude and a result of 1–
3 was classified as a negative attitude. A patient was classi-
fied as having strong knowledge when the answer to the
three questions matched the physician's prescription.
When at least one answer did not match with physician's
prescription the patient was classified as having weak
knowledge about the medical prescription.
The questionnaires of attitudes and knowledge were com-
bined for a serial analysis [18]. This analysis considered a
patient with a positive attitude and strong medical pre-
scription knowledge as having good adherence, and a
patient with a negative attitude or weak medical prescrip-
tion knowledge was classified as having poor adherence.
Descriptive statistics were calculated for the sociodemo-
graphic and clinical characteristics of Type-2 diabetic
patients and for treatment adherence, knowledge, atti-
tudes, and serial analysis. Continuous data with normal
distribution were described using mean and its standard
deviation, or median and quartiles for variables without
normal distribution. These data analyses were conducted
using SPSS 11.0 [19].
Principal component analysis and the internal consist-
ency of the attitudes questionnaire were evaluated using
SPSS [19]. The Medcalc statistical software, v10.0.1 [20]
was used to calculate the sensitivity, specificity, predictive
values, likelihood ratios, and post-test probabilities for
each questionnaire in independent analysis, and for a
serial analysis. This study was approved by the IMSS
Research Committee in Aguascalientes.
Results
Patients responded to interviews about sociodemographic
characteristics, knowledge, and attitudes questionnaires
in a mean time of 10 min.
Sociodemographic and clinical characteristics and adher-
ence percentages are shown in Table 1. Over a half of
patients were female 62.2%, most of them had basic edu-
cation 79.4%, and were married or lived in free unionBMC Public Health 2009, 9:38 http://www.biomedcentral.com/1471-2458/9/38
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76.5%. Mean age was 58.7 ± 9.6. More than half the par-
ticipants suffered hypertension 63.0% and had polyther-
apy prescription 66.0%. The median of duration of
diabetes since first diagnosis was 6 years and median level
of fasting glucose was 8.8 mmol/L, mean HbA1c was
8.8% ± 2.3.
Approximately, a quarter of patients showed good adher-
ence 27.0%. Proxy measurements of adherence as serial
analysis classified patients with good adherence when
they had a strong knowledge and positive attitude, with
27.5%. Considering knowledge and attitudes separately,
their percentages were similar; strong knowledge was
51.6% and positive attitudes was 50.9%.
Table 2 shows the performance of the Medical Prescrip-
tion Knowledge questionnaire; 68.1% of the patients with
good treatment adherence were detected by the question-
naire (sensitivity = 68.1%, 95% C.I. 58.6 – 76.6), 82.2%
of the patients with weak medical prescription knowledge
had poor treatment adherence (negative predictive value
82.2%, 95% C.I. 76.1–87.3), patients with poor adher-
ence are 0.58 times more likely to have weak medical pre-
scription knowledge than patients with good adherence
(negative likelihood ratio = 0.58, 95% C-I- 0.44–0.78). If
a patient had weak medical prescription knowledge, the
patient's probability of having good treatment adherence
reduces from 27% to 16% (Post-test probability of a neg-
ative result = 0.16 95% C.I. 0.10 – 0.25).
Table 1: Characteristics of Type-2 diabetic patients.
CHARACTERISTICS Type-2 diabetic patients
n = 238
Sociodemographic characteristics
Gender
n (%)
Female 148 (62.2)
Male 90 (37.8)
Education level (years) n (%)
Basic education (6c) 189 (79.4)
Intermediate level (7 to 9) 24 (10.1)
Higher education (10≥) 25 (10.5)
Civil status n (%)
Singled 13 (5.5)
Married/Free union 182 (76.5)
Divorced/Widow (er) 43 (18.0)
Age mean (SD) 58.7 (9.6)
Clinical characteristics
Hypertension n (%)
Yes 150 (63.0)
No 88 (37.0)
Prescription n (%)
Monotherapy 81 (34.0)
Polytherapy 157 (66.0)
Duration of diabetes in years
(since first diagnosis)
median (quartiles) 6 (3–12)
Fasting glucose mmol/L median (quartiles) 8.8 (6.9–11.9)
HbA1c % mean (SD) 8.8 (2.3)
Medications
n = 407
Treatment adherence n (%)
Good 110 (27.0)
Poor 297 (73.0)
Medical prescription Knowledge n (%)
Strong 210 (51.6)
Weak 197 (48.4)
Attitude to treatment Adherence n (%)
Positive 207 (50.9)
Negative 200 (49.1)
Combination of knowledge and attitude n (%)
Good 112 (27.5)
Poor 295 (72.5)BMC Public Health 2009, 9:38 http://www.biomedcentral.com/1471-2458/9/38
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Results of the performance of the attitudes toward treat-
ment adherence scale are shown in table 3. These results
were no better than those showed by the Medical Prescrip-
tion Knowledge questionnaire. Although, questionnaires
serial analysis showed an adequate specificity (77.4%,
95% C.I. 72.2–82.0) and a good negative predictive value
(77.9%, 95% C.I. 72.8–82.5), the overall performance of
the serial analysis (table 4) did not exceed the perform-
ance of the Medical Prescription Knowledge question-
naire.
Discussion
Main findings
This study evaluated whether the knowledge question-
naire and attitude scale can be used as proxy measure-
ments of treatment adherence in Type-2 diabetic patients,
using pill count as gold standard.
The study population showed low adherence prevalence
(27.0%), therefore, it is important to explore possible
consequences when adherence prevalence is low. In this
situation, most of the population will not adhere to their
prescriptions, and specific questionnaires might be
expected to be capable of detecting most of the patients
that do not adhere [15]. In this context it is important to
detect patients who do not adhere in order to commence
timely interventions to improve their adherence.
The best performance was identified with the Medical Pre-
scription Knowledge questionnaire. With a negative pre-
dictive value of 82.2%, approximately one in every five
Table 2: Medical prescription knowledge as a proxy measurement of treatment adherence with pill count as gold standard.
MEDICAL PRESCRIPTION KNOWLEDGE TREATMENT ADHERENCE
Good Poor
Strong 75 135 210
Weak 35 162 197
110 297 407
Sensitivity (95% CI): 68.1% (58.6–76.7)
Specificity (95% CI): 54.5% (48.6–60.3)
Positive predictive value (95% CI): 35.7% (29.2–42.6)
Negative predictive value (95% CI): 82.2% (76.1–87.3)
Positive likelihood ratio (95% CI): 1.50 (1.25–1.79)
Negative likelihood ratio (95% CI): 0.58 (0.44–0.78)
Pre-test odds (95% CI): 0.36 (0.28–0.44)
Positive post-test odds (95% CI): 0.54 (0.35–0.78)
Positive post-test probability (95% CI): 0.35 (0.25–0.43)
Negative post-test odds (95% CI): 0.20 (0.12–0.34)
Negative post-test probability (95% CI): 0.16 (0.10–0.25)
Table 3: Attitude toward treatment adherence as a proxy measurement of Treatment adherence with pill count as gold standard.
ATTITUDES TOWARD TREATMENT ADHERENCE TREATMENT ADHERENCE
Good Poor
Positive 63 144 207
Negative 47 153 200
110 297 407
Sensitivity (95% CI): 57.2% (47.4–66.6)
Specificity (95% CI): 51.5% (45.6–57.3)
Positive predictive value (95% CI): 30.4% (24.2–37.1)
Negative predictive value (95% CI): 76.5% (70.0–82.1)
Positive likelihood ratio (95% CI): 1.18 (0.97–1.44)
Negative likelihood ratio (95% CI): 0.83 (0.65–1.06)
Pre-test odds (95% CI): 0.36 (0.28–0.44)
Positive post-test odds (95% CI): 0.42 (0.27–0.63)
Positive post-test probability (95% CI): 0.29 (0.21–0.38)
Negative post-test odds (95% CI): 0.29 (0.18–0.46)
Negative post-test probability (95% CI): 0.22 (0.15–0.31)BMC Public Health 2009, 9:38 http://www.biomedcentral.com/1471-2458/9/38
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patients would be classified as nonadherent, when they
are truly adherent. The post-test probability of a negative
result showed that when a diabetic patient has weak med-
ical prescription knowledge, patient's probability of
adherence reduces from 27% to 16%. Therefore most of
the patients will not have good treatment adherence. A
few adherent patients will be classified as nonadherent,
these patients would unnecessarily be exposed to inter-
ventions to improve adherence. However, this would only
serve to reinforce their adherence at relatively low cost.
Medical Prescription Knowledge questionnaire as proxy
measurement of adherence facilitates the identification of
a significant proportion of patients who do not adhere to
the treatment, and who are candidates for interventions to
improve adherence. This questionnaire provides physi-
cians with information about the patient's knowledge of
medications, dosage, and schedules, which could be
responsible for a patient's nonadherence. This informa-
tion enables physicians to intervene directly by modifying
and/or reinforce patient's treatment knowledge, and even-
tually improve their adherence. It is known that in order
to achieve satisfactory adherence, patients need to possess
adequate knowledge about self-care behaviour [21]. In
contrast, disease knowledge (not medical prescription
knowledge), and self-report do not provide the informa-
tion needed to adopt specific interventions.
Reference to previous literature
Treatment adherence measured with pill count among
our diabetic patients is low 27.0% when compared to
71% in the study of Mason [6] and that of Winkler 57.9%;
although in the latter study the adherence dropped to
25%, when only patients who were prescribed two or
three doses per day were considered [22]. Not only did we
use the same method to measure adherence as they
employed in both studies, but the definition of adherence
applied here was also similar. However, these studies were
restricted to patients who only received monotherapy,
unlike the study carried out here. Polytherapy and doses
prescribed two or three times per day negatively affect
adherence [23], and in our study nearly 66% of the
patients were prescribed two hypoglycemic drugs, and
88% were prescribed two or three doses per day of medi-
cation. Further, the population studied by Winkler [22]
was observed over two months and they were voluntary
patients of a specialized centre who might therefore have
been more motivated. In Mexico, Duran-Varela et al. [24]
identified an adherence of 54.2% using pill count as the
measure of adherence, and over a time frame of 15 days;
this short time period might result in an adherence over-
estimation.
Self-reports and questionnaires are widely used in clinical
practice, and among the most outstanding are the
Morisky-Green questionnaire [12] that evaluates adher-
ence on the basis of patient's behavioural attitudes to
treatment, and Batalla's questionnaire [9] that evaluates
adherence on the basis of a patient's disease knowledge.
The Morisky-Green scale is designed to detect adherent
patients [12]; this scale showed a specificity of 44% and a
negative predictive value of 47%. Hence, it does not detect
almost half the patients that are truly nonadherent. Piñei-
ro et al. [11] and García et al. [10] took nonadherence as
the main event when they validated the Morisky-Green
scale and they identified a sensitivity of 53.1 and 32.0%,
respectively. Thus, from two-third to half of the nonadher-
ent patients were misclassified as adherent.
When self-reporting is used to measure adherence, there
are problems to identify nonadherent patients. When
Haynes et al. [25] took adherence as a main event, they
found 50% specificity, wrongly classifying half the
patients that did not adhere. Similarly, when Piñeiro et al.
[11] used nonadherence as the main event the sensitivity
measured was 32.5%, wrongly classifying nearly two-third
of nonadherent patients. In this latter study, Piñeiro also
validated Batalla's questionnaire with nonadherence as
the main event, defining a positive predictive value of
50.3% [11]. Thus, they classified almost half of the adher-
ent patients as nonadherent, and half would be sent to an
intervention program without needing it. In the studies of
García et al., Piñeiro et al., and Haynes et al., [10,11,25]
pill count was used as a gold standard measurement of
adherence, which was defined as the consumption of 80–
110% of the prescribed medication. This range tends to
overestimate adherence, thereby wrongly classifying non-
adherent patients as adherent.
Table 4: Serial analysis as a proxy measurement of treatment 
adherence with pill count as gold standard.
SERIAL ANALYSIS TREATMENT ADHERENCE
Good Poor
Good 45 67 112
Poor 65 230 295
110 297 407
Sensitivity (95% CI): 40.9% (31.6–50.6)
Specificity (95% CI): 77.4% (72.2–82.0)
Positive predictive value (95% CI): 40.1% (31.0–49.8)
Negative predictive value (95% CI): 77.9% (72.8–82.5)
Positive likelihood ratio (95% CI): 1.8 (1.33–2.47)
Negative likelihood ratio (95% CI): 0.76 (0.65–0.90)
Pre-test odds (95% CI): 0.36 (0.28–0.44)
Positive post-test odds (95% CI): 0.64 (0.37–1.08)
Positive post-test probability (95% CI): 0.39 (0.27–0.51)
Negative post-test odds (95% CI): 0.27 (0.18–0.39)
Negative post-test probability (95% CI): 0.21 (0.15–0.28)BMC Public Health 2009, 9:38 http://www.biomedcentral.com/1471-2458/9/38
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Limitations
The low adherence prevalence in the study population
may have facilitated the good performance of Medical
Prescription Knowledge questionnaire regarding the iden-
tification of nonadherent patients. Consequently, the
questionnaire performance may change in contexts with
higher adherence prevalence because its positive predic-
tive value, positive likelihood ratio, and post-test proba-
bility for a positive result were low. Furthermore, the
results cannot be generalized to all diabetic patients due
to the fact that the study sample in this research did not
have complications or insulin prescription. The presence
of these characteristics could decrease adherence and
affect sensitivity and specificity values.
Suggestions for further research
As Medical Prescription Knowledge questionnaire per-
formance may change in contexts with higher adherence
prevalence, more research is needed before using this
method in this kind of contexts. Moreover, this question-
naire should be tested through telephone interviews. It
would explore the feasibility for covering more diabetic
patients in order to detect risk people for non-adherence.
It could be possible and cheaper because 75.5% of Mexi-
can people have a lane line or a mobile phone [26].
As inadequate functional health literacy has been related
with fewer years of education (≤ 6 years) in diabetic
patients as well as with less knowledge of diabetes, includ-
ing medications knowledge [27]; further research must
measure health literacy along with medical prescription
knowledge in order to improve adherence.
Conclusion
Medical Prescription Knowledge questionnaire showed
the best performance as proxy measurement to identify
non-adherence in type 2 diabetic patients. The best per-
formance was about negative predictive value, negative
likelihood ratio, and post-test probability for a negative
result. However, Medical Prescription Knowledge ques-
tionnaire performance may change in contexts with
higher adherence prevalence. Therefore, more research is
needed before using this method in other contexts.
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